CLDX250117C45000
- 0.10
- 0.000.00%
Celldex Therapeutics Newsroom
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment
Celldex Launches Phase 2 Study Of Barzolvolimab For Atopic Dermatitis, Targeting Mast Cell-Driven Inflammation And Epithelial Barrier Dysfunction With Patient Enrollment Underway
Express News | Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation
Express News | Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Express News | Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of Cdx-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Founder of Celldex Therapeutics Anthony Marucci Buys 40% More Shares
Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
TD Cowen Maintains Celldex Therapeutics(CLDX.US) With Buy Rating
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $80
Celldex Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q3 Revenue $3.2M
Celldex Therapeutics | 8-K: Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Celldex Therapeutics Q3 EPS USD -0.64 Vs. IBES Estimate USD -0.67
Express News | Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Celldex Therapeutics Q3 Operating Expenses USD 55.317 Million